Adam Burgoyne

Associate Professor

UC San Diego Health System
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

TPS577 Background: STAT3 (signal transducer and activator of transcription 3) is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Persistent STAT3 activation has been linked to pathological conditions, including chronic inflammation and fibrosis, both of which play essential roles in the pathogenesis of hepatocellular carcinoma (HCC), and is observed in up to 95% of HCC cases. TTI-101 is a first-in-class, orally delivered, small molecule, direct inhibitor of STAT3 activation. TTI-101 monotherapy demonstrated tumor growth arrest as well as reversal of liver injury and fibrosis in a genetically modified mouse model (Hep Pten - ) which recapitulates the pathogenesis of HCC in non-alcoholic fatty liver disease (NAFLD), as well as in combination with immune checkpoint inhibition in a humanized HCC mouse model. 1,2 TTI-101 monotherapy was found to be well tolerated in a Phase 1 trial conducted in patients (pts) with advanced solid tumors (NCT03195699). Of 15 evaluable HCC pts, 60% demonstrated clinical benefit, including 20% confirmed partial responses (median duration=10.5 months). All pts were relapsed/refractory to standard of care (SOC; median prior systemic therapy=2), including anti-PD-(L)1 based therapy. Methods: NCT05440708 is a multicenter, open-label, study with primary endpoints including safety and efficacy of TTI-101 as monotherapy and in combination with SOC agents. Patients are enrolled to one of three treatment cohorts based upon prior therapy. Cohort A: TTI-101 (monotherapy), pts who have received up to 3 prior lines of systemic therapy. Cohort B: TTI-101 + pembrolizumab, pts who have progressed following ≥ 2 cycles of first-line anti-PD-(L)1 based therapy. Cohort C: TTI-101 + atezolizumab/bevacizumab, patients who are systemic treatment-naïve. The study consists of 2 parts for each cohort (Phase 1b and Phase 2). During Phase 1b, up to 3 dose levels of TTI-101 will be tested for each cohort to determine the RP2D, using a 3+3 design. Subsequent to RP2D determination, enrollment to Phase 2 will commence (Cohort A n=30, Cohort B n=30, Cohort C n=40). Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation based on investigator discretion, or study termination. Secondary and exploratory endpoints include pharmacodynamic effects of TTI-101 and evaluation of candidate biomarkers for anti-tumor activity. Enrollment is simultaneously ongoing in Cohorts A, B, and C of the Phase 1b study. 1. Jung KH, et al. Clin Cancer Res. 2017;23(18):5537-5546. 2. Zhao Y, et al. Hepatology. 2021. Clinical trial information: NCT05440708 .

Year:

2024

547 Background: Causes of variable disease response to first-line treatment with atezolizumab/bevacizumab (atezo/bev) in hepatocellular carcinoma (HCC) patients remain unclear. Identifying tumor markers that predict treatment efficacy may help raise clinical suspicion for early disease progression. The role of des-gamma-carboxy prothrombin (DCP) is not well established in Hepatitis B Virus (HBV) non-endemic areas. This study aimed to investigate DCP as a predictive biomarker of atezo/bev treatment response in HCC patients. Methods: This single-center retrospective analysis evaluated DCP and radiographic response in HCC patients who received atezo/bev in the first-line setting. DCP was measured at the time of best response evaluation and compared to day one of atezo/bev initiation. Elevated DCP was defined by >=7.5 ng/mL. DCP response was defined as a decrease of >=50% at response assessment compared with baseline. Treatment response was evaluated based on imaging modalities including computed tomography and/or magnetic resonance imaging. Objective response rate (ORR) was defined as the percentage of patients with complete response (CR) and partial response (PR). Disease control rate (DCR) was defined as the percentage of patients with CR, PR, and stable disease (SD). No Response (NR) was defined as the percentage of patients with SD and PD. Comparisons of treatment effects were performed using two-tailed Fisher Exact Probability Test. Results: A total of 53 HCC patients treated with atezo/bev as first-line therapy were included. The best treatment responses according to radiographic evaluation were as follows: CR 3.8%, PR 22.6%, SD 52.8%, and PD 20.8%, respectively. Patients with DCP response had ORR of 69% (odds ratio, 15.75; 95% CI, 3.50-70.9; P=.0002) and DCR of 100% ( P=.047). Patients with >=50% increase in DCP at response evaluation compared to day one of treatment had ORR of 4.5% and NR of 95% ( P=.0035). On day one of treatment, 70% of patients had an elevated DCP. There was no difference between elevated DCP vs non-elevated DCP on day one of treatment and ORR. Conclusions: This study found that DCP has utility in predicting response to atezo/bev for HCC patients in HBV non-endemic areas. Further studies are needed to confirm findings and evaluate the prognostic implications of DCP in HBV non-endemic areas.

Year:

2024

534 Background: With numerous advances in systemic therapy for advanced hepatocellular carcinoma (HCC) over the past several years, there are now multiple first-line treatment options which can be considered. These options include combination atezolizumab with bevacizumab (atezo/bev), programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) targeted agents, and oral multikinase inhibitor monotherapy. However, further guidance is needed to predict which patients will respond to best to each regimen. Methods: We performed a single center, retrospective study to determine the association between responses to first-line therapies in advanced HCC and various molecular alterations. Patients received first-line therapy with either atezo/bev, PD-1/PD-L1 monotherapy, or oral multikinase inhibitor monotherapy with treatment responses determined by imaging. All patients underwent next-generation sequencing (NGS) with testing performed on peripheral blood or tumor tissue. Results: A total of 116 patients with advanced HCC were included in this study. For first-line therapies, 45 (38.8%) patients received atezo/bev, 41 (35.3%) received oral multikinase inhibitor monotherapy, and 30 (25.9%) received PD-1/PD-L1 monotherapy. There was no association between treatment responses and patient ethnicity, age, or underlying cirrhosis etiology for any regimen. However, when analyzing NGS results, atezo/bev recipients with telomerase reverse transcriptase (TERT) promoter alterations had significantly higher rates of disease progression (PD) compared those without TERT promoter alterations (91.7% vs 54.6%, p = 0.03). In addition, in the oral multikinase inhibitor monotherapy group, those with CTNNB1 alterations had significantly greater PD rates compared to patients without these alterations (66.7% vs 31%, p = 0.04). There were no significant correlations between molecular alterations and responses in the PD-1/PD-L1 monotherapy group (Table). Conclusions: In our study, advanced HCC patients who received first-line systemic therapies were found to have significant correlations between TERT promoter and CTNNB1 alterations and responses to atezo/bev and oral multikinase inhibitor monotherapy, respectively. Given the widespread use of these regimens in the HCC treatment paradigm, additional studies are needed to confirm these findings and determine their impact on survival outcomes.[Table: see text]

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Christopher L. Bowlus

University of California, Davis

UNITED STATES
View details

James Park

Professor/System Chief

University of Washington

UNITED STATES
View details

MEHMET AKCE

Associate Professor

The University of Alabama

UNITED STATES
View details

Santiago Ponce Aix

Head of Therapeutic Innovation and Precision Medicine

Hospital Universitario 12 de Octubre

SPAIN
View details

kathryn fowler

Associate Professor

University of California, San Diego

UNITED STATES
View details

Sajid Khan

Associate Professor, Section Chief

Yale University

UNITED STATES
View details

Kit Curtius

Research Health Scientist (PI)

University of California, San Diego

UNITED STATES
View details